Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.
Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long ...
Metsera files for IPO, developing GLP-1 drug MET-097i and other obesity treatments to compete with Eli Lilly and Novo Nordisk ...
An FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment ...
China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites ...
Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where ...
Eli Lilly is expanding its private financing ambitions, partnering with venture capital firm Andreessen Horowitz on a new ...
Dyne Therapeutics touted an early-stage study of its RNA treatment for myotonic dystrophy type 1 and has selected the dose it ...
Moderna CSO, launches Kerna Labs with $6M seed funding to develop AI models for better mRNA drugs, partnering with Julia Peng ...
Windward Bio, Kardigan, Ouro Medicines & Timberlyne Therapeutics. Three licensed drugs from Chinese firms, while Kardigan has ...
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback